Fluoroquinolone-resistant Pseudomonas aeruginosa: Risk factors for acquisition and impact on outcomes

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 4, 2005, Pages 535-541

  Hsu, Donald I ^a,b   Okamoto, Mark P ^c   Murthy, Rekha ^d   Wong Beringer, Annie ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Empirical prescribing; Levofloxacin; Mortality; Multidrug resistance

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SENSITIVITY; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORTALITY; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 17444363436     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki026     Document Type: Article

References (27)

1. Richards, M. J., Edwards, J. R., Culver, D. H. et al. (1999). Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Critical Care Medicine 27, 887-92.
2. Burwen, D. R., Banerjee, S. N. & Gaynes, R. P. (1994). Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. Journal of Infectious Diseases 170, 1622-5.
3. Quinn, J. P., Dudek, E. J., DiVincenzo, C. A. et al. (1986). Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. Journal of Infectious Diseases 154, 289-94.
4. Giamarellou, H. & Antoniadou, A. (2001). Antipseudomonal antibiotics. Medical Clinics of North America 85, 19-41.
5. McCaig, L. F., Besser, R. E. & Hughes, J. M. (2003). Antimicrobial drug prescriptions in ambulatory care settings, United States, 1992-2000. Emerging Infectious Diseases 9, 432-7.
6. Neuhauser, M. M., Weinstein, R. A., Rydman, R. et al. (2003). Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. Journal of the American Medical Association 289, 885-8.
7. Peterson, L. R., Postelnick, M., Pozdol, T. L. et al. (1998). Management of fluoroquinolone resistance in Pseudomonas aeruginosa - outcome of monitored use in a referral hospital. International Journal of Antimicrobial Agents 10, 207-14.
8. Ryan, K.A., Steward, C.D., Tenover, F.C. et al. (2002). Association between carbapenem and fluoroquinolone resistance among Project ICARE Pseudomonas aeruginosa isolates. In Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract C2-306. American Society for Microbiology, Washington, DC, USA.
9. Carmeli, Y., Troillet, N., Karchmer, A. W. et al. (1999). Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Archives of Internal Medicine 159, 1127-32.
10. Harris, A., Torres-Viera, C., Venkataraman, L. et al. (1999). Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clinical Infectious Diseases 28, 1128-33.
11. Carmeli, Y., Troillet, N., Eliopoulos, G. M. et al. (1999). Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrobial Agents and Chemotherapy 43, 1379-82.
12. National Committee for Clinical Laboratory Standards. (2000). Performance Standards for Antimicrobial Disk Susceptibility Tests: M100-S12. NCCLS, Wayne, PA, USA.
13. Garner, J. S., Jarvis, W. R., Emori, T. G. et al. (1988). CDC definitions for nosocomial infections. American Journal of Infection Control 16, 128-40.
14. Polk, R. E., Johnson, C. K., McClish, D. et al. (2004). Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clinical Infectious Diseases 39, 497-503.
15. Malcolm, C. & Marrie, T. J. (2003). Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Archives of Internal Medicine 163, 797-802.
16. National Nosocomial Infections Surveillance (NNIS). (2003). National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2003, issued August 2003. American Journal of Infection Control 31, 481-98.
17. Flamm, R. K., Weaver, M. K., Thornsberry, C. et al. (2004). Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999-2002. Antimicrobial Agents and Chemotherapy 48, 2431-6.
18. Lautenbach, E., Fishman, N. O., Bilker, W. B. et al. (2002). Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Archives of Internal Medicine 162, 2469-77.
19. Hancock, R. E. (1998). Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clinical Infectious Diseases 27, Suppl. 1, S93-9.
20. Poole, K. (2000). Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrobial Agents and Chemotherapy 44, 2233-41.
21. Kriengkauykiat, J., Porter, E., Lomovskaya, O. et al. (2005). Use of an efflux pump inhibitor to determine efflux pump mediated fluoroquinolone resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 49, 565-70.
22. Kollef, M. H., Sherman, G., Ward, S. et al. (1999). Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115, 462-74.
23. Chamot, E., Boffi El Amari, E., Rohner, P. et al. (2003). Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrobial Agents and Chemotherapy 47, 2756-64.
24. Kang, C. I., Kim, S. H., Kim, H. B. et al. (2003). Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clinical Infectious Diseases 37, 745-51.
25. Knaus, W. A., Draper, E. A., Wagner, D. P. et al. (1985). APACHE II: a severity of disease classification system. Critical Care Medicine 13, 818-29.
26. Kaye, K. S., Engemann, J. J., Mozaffari, E. et al. (2004). Reference group choice and antibiotic resistance outcomes. Emerging Infectious Diseases 10, 125-8.
27. Spellberg, B., Powers, J. H., Brass, E. P. et al. (2004). Trends in antimicrobial drug development: implications for the future. Clinical Infectious Diseases 38, 1279-86.